Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma
- 8 February 2007
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 29 (3), 211-220
- https://doi.org/10.1002/hed.20505
Abstract
Background. Our aim was to correlate patterns of failure with target volume delineations in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity‐modulated radiation therapy (IMRT) and to report subjective xerostomia outcomes after IMRT as compared with conventional radiation therapy (CRT). Methods. Between January 2000 and April 2005, 69 patients with newly diagnosed nonmetastatic HNSCC underwent curative parotid‐sparing IMRT at Stanford University. Sites included were oropharynx (n = 39), oral cavity (n = 8), larynx (n = 8), hypopharynx (n = 8), and unknown primary (n = 6). Forty‐six patients received definitive IMRT (66 Gy, 2.2 Gy/fraction), and 23 patients received postoperative IMRT (60.2 Gy, 2.15 Gy/fraction). Fifty‐one patients also received concomitant chemotherapy. Posttreatment salivary gland function was evaluated by a validated xerostomia questionnaire in 29 IMRT and 75 matched CRT patients >6 months after completing radiation treatment. Results. At a median follow‐up of 25 months for living patients (range, 10–60), 7 locoregional failures were observed, 5 in the gross target or high‐risk postoperative volume, 1 in the clinical target volume, and 1 at the junction of the IMRT and supraclavicular fields. The 2‐year Kaplan–Meier estimates for locoregional control and overall survival were 92% and 74% for definitive IMRT and 87% and 87% for postoperative IMRT patients, respectively. The mean total xerostomia questionnaire score was significantly better for IMRT than for CRT patients (p = .006). Conclusions. The predominant pattern of failure in IMRT‐treated patients is in the gross tumor volume. Parotid sparing with IMRT resulted in less subjective xerostomia and may improve quality of life in irradiated HNSCC patients. © 2006 Wiley Periodicals, Inc. Head Neck, 2007Keywords
This publication has 46 references indexed in Scilit:
- Matched case–control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial reportInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experienceInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experienceInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experienceInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14Journal of Clinical Oncology, 2005
- A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRTInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Variations in target delineation for head and neck IMRT: An international multi-institutional studyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Preservation of oral health–related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- 106 Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week-report from the Dahanca 7 trialInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995